Log in

Relevant bibliographies by topics / Cannabis / Journal articles

Journal articles on the topic 'Cannabis'

To see the other types of publications on this topic, follow the link: Cannabis.

Author: Grafiati

Published: 4 June 2021

Last updated: 28 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cannabis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Harishchandra, Dulanjalee Lakmali, Sukanya Haituk, Patchareeya Withee, Nisachon Tamakaew, Nittaya Nokum, Chaorai Kanchanomai, Tonapha Pusadee, Chiharu Nakashima, and Ratchadawan Cheewangkoon. "First Molecular Phylogenetic Identification and Report of Pseudocercospora cannabina Causing Leaf Spot Disease on Cannabis sativa in Thailand." Horticulturae 9, no. 12 (November 23, 2023): 1261. http://dx.doi.org/10.3390/horticulturae9121261.

Full text

Abstract:

Cannabis sativa is gaining attention as an agronomically important crop in many countries around the world. The identification and control of leaf diseases in cannabis are very important for cannabis cultivators as leaves are the most economically important part of the cannabis plants. In 2022, several cannabis plants in cultivations showing olive leaf spot symptoms emerged from Chiang Rai province, Thailand. Preliminary studies indicated that the causal organism is Pseudocercospora sp. Species of Pseudocercospora are important plant pathogens that are now identified through morphological studies combined with DNA sequence data of Internal Transcribed Spacer (ITS), Actin (act), Translation Elongation Factor (tef), and RNA Polymerase II second largest subunit (rpb2) gene regions. We aimed to investigate and understand the emergence of olive leaf spot disease in cannabis plants in Chiang Rai province, Thailand, with a specific focus on the combined morpho-molecular identification of the pathogen. In our study, Pseudocercospora cannabina, the causal organism of olive leaf spot disease, was identified as the leaf spot-causing pathogen with both morphological and phylogenetic analyses. Our study is the first to provide molecular data for Ps. cannabina as the typenor Ps. cannabina isolates from previous studies have made molecular data available for this species. A pathogenicity test, re-isolation, and identification steps were performed to fulfill Koch’s postulates. This comprehensive approach enhances our understanding of the olive leaf spot disease and its causative agent in cannabis.

APA, Harvard, Vancouver, ISO, and other styles

2

Al-Khazaleh, Ahmad K., Xian Zhou, Deep Jyoti Bhuyan, Gerald W. Münch, Elaf Adel Al-Dalabeeh, Kayla Jaye, and Dennis Chang. "The Neurotherapeutic Arsenal in Cannabis sativa: Insights into Anti-Neuroinflammatory and Neuroprotective Activity and Potential Entourage Effects." Molecules 29, no. 2 (January 15, 2024): 410. http://dx.doi.org/10.3390/molecules29020410.

Full text

Abstract:

Cannabis, renowned for its historical medicinal use, harbours various bioactive compounds—cannabinoids, terpenes, and flavonoids. While major cannabinoids like delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have received extensive scrutiny for their pharmacological properties, emerging evidence underscores the collaborative interactions among these constituents, suggesting a collective therapeutic potential. This comprehensive review explores the intricate relationships and synergies between cannabinoids, terpenes, and flavonoids in cannabis. Cannabinoids, pivotal in cannabis’s bioactivity, exhibit well-documented analgesic, anti-inflammatory, and neuroprotective effects. Terpenes, aromatic compounds imbuing distinct flavours, not only contribute to cannabis’s sensory profile but also modulate cannabinoid effects through diverse molecular mechanisms. Flavonoids, another cannabis component, demonstrate anti-inflammatory, antioxidant, and neuroprotective properties, particularly relevant to neuroinflammation. The entourage hypothesis posits that combined cannabinoid, terpene, and flavonoid action yields synergistic or additive effects, surpassing individual compound efficacy. Recognizing the nuanced interactions is crucial for unravelling cannabis’s complete therapeutic potential. Tailoring treatments based on the holistic composition of cannabis strains allows optimization of therapeutic outcomes while minimizing potential side effects. This review underscores the imperative to delve into the intricate roles of cannabinoids, terpenes, and flavonoids, offering promising prospects for innovative therapeutic interventions and advocating continued research to unlock cannabis’s full therapeutic potential within the realm of natural plant-based medicine.

APA, Harvard, Vancouver, ISO, and other styles

3

Watson, C. Wei-Ming, Laura M. Campbell, Ni Sun-Suslow, Suzi Hong, Anya Umlauf, Ronald J. Ellis, Jennifer E. Iudicello, et al. "Daily Cannabis Use is Associated With Lower CNS Inflammation in People With HIV." Journal of the International Neuropsychological Society 27, no. 6 (July 2021): 661–72. http://dx.doi.org/10.1017/s1355617720001447.

Full text

Abstract:

AbstractObjective:Recent cannabis exposure has been associated with lower rates of neurocognitive impairment in people with HIV (PWH). Cannabis’s anti-inflammatory properties may underlie this relationship by reducing chronic neuroinflammation in PWH. This study examined relations between cannabis use and inflammatory biomarkers in cerebrospinal fluid (CSF) and plasma, and cognitive correlates of these biomarkers within a community-based sample of PWH.Methods:263 individuals were categorized into four groups: HIV− non-cannabis users (n = 65), HIV+ non-cannabis users (n = 105), HIV+ moderate cannabis users (n = 62), and HIV+ daily cannabis users (n = 31). Differences in pro-inflammatory biomarkers (IL-6, MCP-1/CCL2, IP-10/CXCL10, sCD14, sTNFR-II, TNF-α) by study group were determined by Kruskal–Wallis tests. Multivariable linear regressions examined relationships between biomarkers and seven cognitive domains, adjusting for age, sex/gender, race, education, and current CD4 count.Results:HIV+ daily cannabis users showed lower MCP-1 and IP-10 levels in CSF compared to HIV+ non-cannabis users (p = .015; p = .039) and were similar to HIV− non-cannabis users. Plasma biomarkers showed no differences by cannabis use. Among PWH, lower CSF MCP-1 and lower CSF IP-10 were associated with better learning performance (all ps < .05).Conclusions:Current daily cannabis use was associated with lower levels of pro-inflammatory chemokines implicated in HIV pathogenesis and these chemokines were linked to the cognitive domain of learning which is commonly impaired in PWH. Cannabinoid-related reductions of MCP-1 and IP-10, if confirmed, suggest a role for medicinal cannabis in the mitigation of persistent inflammation and cognitive impacts of HIV.

APA, Harvard, Vancouver, ISO, and other styles

4

Ličanin, Ifeta, and Amira Redžić. "Psycho-Social Characteristics of Cannabis Abusing Youth." Bosnian Journal of Basic Medical Sciences 5, no. 1 (February 20, 2005): 72–76. http://dx.doi.org/10.17305/bjbms.2005.3339.

Full text

Abstract:

It is a well known fact that drug abuse is most common in early adolescence. The most popular substances among youth are cannabis products (made from Cannabis sativa L., Cannaba-ceae). The majority of heroin and cocaine addicts have started with marijuana. The aim of this study is to show some psycho-social characteristics of adolescents who abuse cannabis. Research conducted during the year 2001 was epidemiological and prospective. The study group included 600 adolescents of equal gender and age distribution. Q 2000 questionnaire was used, as a comprehensive tool for all aspects of adolescent life. The results show strong peer impact on one’s behavior. Youth who use cannabis had 2-3 friends of the same behavior, compared to others who had none. We found positive correlation between life stressful events and cannabis abuse. We also noticed tendency to delinquent behavior related to cannabis abuse (35%).

APA, Harvard, Vancouver, ISO, and other styles

5

Iftikhar, Amna, Umaima Zafar, Waqar Ahmed, Muhammad Asim Shabbir, Aysha Sameen, Amna Sahar, Zuhaib F. Bhat, Przemysław Łukasz Kowalczewski, Maciej Jarzębski, and Rana Muhammad Aadil. "Applications of Cannabis Sativa L. in Food and Its Therapeutic Potential: From a Prohibited Drug to a Nutritional Supplement." Molecules 26, no. 24 (December 20, 2021): 7699. http://dx.doi.org/10.3390/molecules26247699.

Full text

Abstract:

Hemp (Cannabis sativa L.) is a herbaceous anemophilous plant that belongs to the Cannabinaceae family. The cannabis seed (hemp) has long been utilized as a food source and is commercially important as an edible oil source. In this review, the positive and negative health effects of cannabis, the relationship between cannabis and various diseases, and the use of cannabis in various food products have been discussed. In addition, the scientific literature on the potential use of cannabis and its derivatives as a dietary supplement for the prevention and treatment of inflammatory and chronic degenerative diseases in animals and humans has been reviewed. Cannabis is being developed as a key ingredient in a variety of food items, including bakery, confectionery, beverages, dairy, fruits, vegetables, and meat. Hemp seeds are high in readily digestible proteins, lipids, polyunsaturated fatty acids (PUFA), insoluble fiber, carbs, and favorable omega-6 PUFA acid to omega-3 PUFA ratio and have high nutritional value. The antioxidants of cannabis, such as polyphenols, help with anxiety, oxidative stress, and the risk of chronic illnesses, including cancer, neurological disorders, digestive problems, and skin diseases. Cannabis has been shown to have negative health impacts on the respiratory system, driving, and psychomotor functions, and the reproductive system. Overall, the purpose of this research is to stimulate more in-depth research on cannabis’s adaptation in various foods and for the treatment of chronic illnesses.

APA, Harvard, Vancouver, ISO, and other styles

6

Smith, D. E., and R. B. Seymour. "Cannabis and cannabis withdrawal." Journal of Substance Misuse 2, no. 1 (January 1997): 49–53. http://dx.doi.org/10.3109/14659899709084617.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Hübner, Jutta. "Cannabis, Hanf (Cannabis sativa)." Onkologische Welt 01, no. 05 (2010): 200. http://dx.doi.org/10.1055/s-0038-1632891.

Full text

Abstract:

Cannabis oder Hanf wird im Freiland je nach Sorte zwischen ca. 50 cm bis 8 m hoch, in europäischen Breitengraden maximal ca. 4 m, wobei 2 m als realistisch angesehen werden sollten. Zur medizinischen Verwendung kommt meist der Indische Hanf (Cannabis sativa indica).

APA, Harvard, Vancouver, ISO, and other styles

8

McPartland, John M., and Ethan B. Russo. "Cannabis and Cannabis Extracts." Journal of Cannabis Therapeutics 1, no. 3-4 (June 2001): 103–32. http://dx.doi.org/10.1300/j175v01n03_08.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Lapierre, Éliana, Maxime de Ronne, Rosemarie Boulanger, and Davoud Torkamaneh. "Comprehensive Phenotypic Characterization of Diverse Drug-Type Cannabis Varieties from the Canadian Legal Market." Plants 12, no. 21 (November 2, 2023): 3756. http://dx.doi.org/10.3390/plants12213756.

Full text

Abstract:

Cannabis (Cannabis sativa L.) stands as a historically significant and culturally important plant, embodying economic, social, and medicinal relevance for human societies. However, years of prohibition and stigmatization have hindered the cannabis research community, which is hugely undersized and suffers from a scarcity of understanding of cannabis genetics and how key traits are expressed or inherited. In this study, we conducted a comprehensive phenotypic characterization of 176 drug-type cannabis accessions, representative of Canada’s legal market. We assessed germination methods, evaluated various traits including agronomic, morphological, and cannabinoid profiles, and uncovered significant variation within this population. Notably, the yield displayed a negative correlation with maturity-related traits but a positive correlation with the fresh biomass. Additionally, the potential THC content showed a positive correlation with maturity-related traits but a negative correlation with the yield. Significant differences were observed between the plants derived from regular female seeds and feminized seeds, as well as between the plants derived from cuttings and seeds for different traits. This study advances our understanding of cannabis cultivation, offering insights into germination practices, agronomic traits, morphological characteristics, and biochemical diversity. These findings establish a foundation for precise breeding and cultivar development, enhancing cannabis’s potential in the legal market.

APA, Harvard, Vancouver, ISO, and other styles

10

da Costa-Oliveira, Claudete, Michele Lafayette Pereira, Nicole Ferrari de Carvalho, Luiza Aparecida Luna Silvério, Ygor Jessé Ramos, and Priscila Gava Mazzola. "Exploring the Significance of Pharmaceutical Care in Mental Health: A Spotlight on Cannabis." Pharmacy 12, no. 4 (June 27, 2024): 100. http://dx.doi.org/10.3390/pharmacy12040100.

Full text

Abstract:

Although preliminary evidence suggests Cannabis’s efficacy in symptom control for anxiety and depression—psychiatric disorders that significantly impact mental health—much remains to be understood about its effects on the central nervous system (CNS) and how to optimize treatment for these disorders. This study aims to conduct a narrative review to evaluate pharmaceutical care in treating symptoms of anxiety and depression alongside Cannabis use, focusing on safety and therapeutic efficacy optimization. We seek to conceptualize anxiety and depression disorders, review evidence on Cannabis use, evaluate the evidence quality, and identify knowledge gaps. Twelve articles were identified, revealing a significant gap in the literature regarding the integration of pharmaceutical care with Cannabis-based therapies, specifically for anxiety and depression. Despite a growing interest in the relationship between Cannabis and mental health, current research is insufficient for a comprehensive understanding. The relationship between Cannabis use and anxiety and depression disorders requires further, more targeted investigations. This study underscores the importance of future research to fill existing gaps, providing informed insights and robust guidelines for the safe and effective use of Cannabis as part of the treatment for anxiety and depression. It is crucial that pharmaceutical care integrates these therapies responsibly to improve the overall well-being of patients.

APA, Harvard, Vancouver, ISO, and other styles

11

Sciacca, Claudia, Nunzio Cardullo, and Vera Muccilli. "2,3-Bis((E)-4-hydroxybenzylidene)-N1,N4-bis(4-methylbenzyl)succinamide." Molbank 2023, no. 1 (January 17, 2023): M1558. http://dx.doi.org/10.3390/m1558.

Full text

Abstract:

Lignans and neolignans are dimeric natural products with an extraordinary variety of structures and biological properties. Diphenylbutadienes are a subclass of lignans rarely found in nature with cannabisin G being the most representative example. This lignan, found in Cannabis sativa seed, has shown anti-inflammatory and antioxidant activity among other biological properties. Different methodologies have been reported for the synthesis of cannabis G to be employed in new biological studies. We report herein a green and concise procedure based on the use of Trametes versicolor laccase for the synthesis of a new diphenylbutadiene. The developed procedure may be employed for the synthesis of cannabisin G and other analogues.

APA, Harvard, Vancouver, ISO, and other styles

12

Earleywine, Mitch, Luna F. Ueno, Maha N. Mian, and Brianna R. Altman. "Cannabis-induced oceanic boundlessness." Journal of Psychopharmacology 35, no. 7 (March 28, 2021): 841–47. http://dx.doi.org/10.1177/0269881121997099.

Full text

Abstract:

Background: Despite tetrahydrocannabinol (THC)’s reputation for creating dramatic effects at high doses, empirical work rarely addresses cannabis’s impact on subjective responses common to the tryptamine psychedelics. We focused on these effects because they have preceded and covaried with the therapeutic impact of psilocybin in previous work. Aims: The current study examined if self-reported responses to cannabis products might parallel those found in clinical trials of psilocybin administration. We also investigated if measures of demographics and cannabis use might correlate with these responses. Methods: Participants reported the subjective effect of their highest THC experience using 27 items that assess oceanic boundlessness, a correlate of mystical experiences. They also answered infrequency items and questions on demographics and cannabis consumption. Results: In an effort to address concerns about replication, we divided respondents who passed infrequency items into two random samples. Self-reported “breakthrough” experiences were significantly greater than zero but significantly lower than those reported in randomized clinical trials of psilocybin (17–19% vs. 59%). Total scores covaried with perceived dosages of THC, but only in one sample. Heavier users of cannabis reported lower scores. Conclusions: Self-report data suggest that high doses of cannabis can create subjective effects comparable to those identified in trials of psilocybin that precede relief from cancer-related distress, treatment-resistant depression, alcohol problems, and cigarette dependence. Given the disparate mechanisms of action, comparing THC-induced to psilocybin-induced effects might improve our understanding of the mechanisms underlying subjective experiences. This work might also support the development of a cannabis-assisted psychotherapy comparable to psilocybin-assisted psychotherapy.

APA, Harvard, Vancouver, ISO, and other styles

13

Solowij, Nadia, and Nicole Pesa. "Anormalidades cognitivas no uso da cannabis." Revista Brasileira de Psiquiatria 32, suppl 1 (May 2010): 531–40. http://dx.doi.org/10.1590/s1516-44462010000500006.

Full text

Abstract:

OBJETIVO: Evidências de que o uso de cannabis prejudica funções cognitivas em humanos têm-se acumulado nas décadas recentes. O propósito desta revisão é o de atualizar o conhecimento nesta área com novos achados a partir da literatura mais recente. MÉTODO: As buscas na literatura foram realizadas utilizando-se o banco de dados Web of Science até fevereiro de 2010. Foram buscados os termos "cannabi*" ou "marijuana" e "cogniti*" ou "memory" ou "attention" ou "executive function", e os estudos em humanos foram revisados preferencialmente em relação aos estudos em animais. DISCUSSÃO: O uso de cannabis prejudica a memória, a atenção, o controle inibitório, as funções executivas e a tomada de decisões, tanto durante como após o período de intoxicação aguda, persistindo por horas, dias, semanas ou mais após o último uso. Os estudos de desafio farmacológico em humanos estão elucidando a natureza e os substratos neurais das alterações cognitivas associadas a vários canabinoides. O uso pesado ou de longo prazo de cannabis parece resultar em anormalidades cognitivas mais duradouras e possivelmente em alterações cerebrais estruturais. Efeitos cognitivos adversos maiores estão associados ao uso de cannabis quando este começa no início da adolescência. CONCLUSÃO: O sistema canabinoide endógeno está envolvido nos mecanismos de regulação neural que modulam os processos subjacentes a uma gama de funções cognitivas que estão prejudicadas pela cannabis. Os déficits em usuários humanos muito provavelmente refletem, portanto, neuroadaptações e o funcionamento alterado do sistema canabinoide endógeno.

APA, Harvard, Vancouver, ISO, and other styles

14

Coomber, Ross, Michael Oliver, and Craig Morris. "Using Cannabis Therapeutically in the UK: A Qualitative Analysis." Journal of Drug Issues 33, no. 2 (April 2003): 325–56. http://dx.doi.org/10.1177/002204260303300204.

Full text

Abstract:

Thirty-three therapeutic cannabis users in England were interviewed about their experiences using an illegal drug for therapeutic purposes. Interviews were semi-structured, and responses highly qualitative. Particular issues included how and why cannabis was used therapeutically; what problems its illegality posed in terms of access, cost, reliability of supply, and quality of the product; the perceived beneficial effects of its use; and unwanted effects (problems in relation to family, friends, partners, the criminal justice system, and the health care system). The study did not seek to prove or disprove the efficacy of cannabis used as a therapeutic agent merely to report the experiences of those who use it in that way. It was found that users perceived cannabis to be highly effective in treating their symptoms, to complement existing medication, and to produce fewer unwanted effects. Smoking was the preferred method of administration, permitting greater control over dose and administration. Problems related to prescribed medication motivated many to use cannabis therapeutically. Few problems were experienced with friends, family, partners, and the criminal justice or health care systems, although other concerns about cannabis's illegality were reported. Although most were relatively unconcerned about the risk involved and were determined to continue use, many resented that they felt they were being forced to break the law. Problems relating to access to the drug (in an illegal context) and managing its administration were reported. A brief discussion of the continued prohibition of cannabis for this group is undertaken, and a harm reduction approach is suggested.

APA, Harvard, Vancouver, ISO, and other styles

15

Robson, P. "Cannabis." Archives of Disease in Childhood 77, no. 2 (August 1, 1997): 164–66. http://dx.doi.org/10.1136/adc.77.2.164.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Grayson, Michelle. "Cannabis." Nature 525, no. 7570 (September 2015): S1. http://dx.doi.org/10.1038/525s1a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Frost, Elizabeth A. M. "Cannabis." Topics in Pain Management 33, no. 8 (March 2018): 1–6. http://dx.doi.org/10.1097/01.tpm.0000530953.56127.59.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Vale, Allister. "Cannabis." Medicine 31, no. 10 (October 2003): 40. http://dx.doi.org/10.1383/medc.31.10.40.27812.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Warf, Barney. "Cannabis." AAG Review of Books 3, no. 4 (September 30, 2015): 160–61. http://dx.doi.org/10.1080/2325548x.2015.1077425.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Vale, Allister. "Cannabis." Medicine 35, no. 11 (November 2007): 603. http://dx.doi.org/10.1016/j.mpmed.2007.08.020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Wiley, Jenny L. "Cannabis." Pharmacology Biochemistry and Behavior 64, no. 2 (October 1999): 257–60. http://dx.doi.org/10.1016/s0091-3057(99)00059-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Brody, Herb. "Cannabis." Nature 572, no. 7771 (August 28, 2019): S1. http://dx.doi.org/10.1038/d41586-019-02523-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Bonnet, U., and J. Reimer. "Cannabis." Suchttherapie 17, no. 02 (May 4, 2016): 60. http://dx.doi.org/10.1055/s-0042-105348.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Wiley, J. L. "CANNABIS." Behavioural Pharmacology 9, no. 1 (August 1998): S125. http://dx.doi.org/10.1097/00008877-199808000-00290.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Wiley, J. L. "CANNABIS." Behavioural Pharmacology 9, Supplement (August 1998): S125. http://dx.doi.org/10.1097/00008877-199808001-00290.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Wiley, J. L. "CANNABIS." Behavioural Pharmacology 9, no. 1 (August 1998): S125. http://dx.doi.org/10.1097/00008877-199812001-00290.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Jaury, P. "Cannabis." EMC - Traité de médecine AKOS 1, no. 1 (January 2006): 1–6. http://dx.doi.org/10.1016/s1634-6939(06)41343-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Jaury, P. "Cannabis." EMC - Tratado de Medicina 10, no. 2 (January 2006): 1–6. http://dx.doi.org/10.1016/s1636-5410(06)70385-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Mura, Patrick, and Paul Lafargue. "Cannabis." EMC - Biologie Médicale 1, no. 1 (January 2006): 1–4. http://dx.doi.org/10.1016/s2211-9698(06)76336-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Haller, Reinhard, and Isabell Dittrich. "Cannabis." Psychiatrie und Psychotherapie 1, no. 2 (December 2005): 39–50. http://dx.doi.org/10.1007/s11326-005-0008-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Cremer-Schaeffer, Peter, and Winfried Häuser. "Cannabis." Der Schmerz 33, no. 5 (September 30, 2019): 375–77. http://dx.doi.org/10.1007/s00482-019-00396-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

. "Cannabis." Medisch-Farmaceutische Mededelingen 37, no. 9 (September 1999): 216. http://dx.doi.org/10.1007/bf03057395.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Van Kerckhove, Zeen. "Cannabis." TBV – Tijdschrift voor Bedrijfs- en Verzekeringsgeneeskunde 32, no. 1 (January 2024): 50. http://dx.doi.org/10.1007/s12498-023-2460-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Peng, Han, and Fereidoon Shahidi. "Cannabis and Cannabis Edibles: A Review." Journal of Agricultural and Food Chemistry 69, no. 6 (February 8, 2021): 1751–74. http://dx.doi.org/10.1021/acs.jafc.0c07472.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Lynskey, Michael, and Wayne Hall. "Cannabis use and cannabis use disorders." Lancet Psychiatry 3, no. 10 (October 2016): 911–12. http://dx.doi.org/10.1016/s2215-0366(16)30270-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Charles, Christopher A. D. "Creating Cannabis Identity through Cannabis Use." Caribbean Quarterly 69, no. 3-4 (October 2, 2023): 386–401. http://dx.doi.org/10.1080/00086495.2023.2295566.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Nelson, Peter L. "Cannabis Amotivational Syndrome and Personality Trait Absorption: A Review and Reconceptualization." Imagination, Cognition and Personality 14, no. 1 (September 1994): 43–58. http://dx.doi.org/10.2190/uey1-lk8p-h5d0-1gt8.

Full text

Abstract:

This article argues that the so-called cannabis “amotivation syndrome,” widely reported in the literature, may not be a single nosological entity, but represent, instead, a change in cognitive style emerging as a result of cannabis's ability to facilitate a unique attentional state favoured by those who have a higher than average level of a personality factor referred to as “trait absorption.” Exaggeration of the absorptive style of cognition through cannabis use, when taken in the context of either a pre-existing or a reactive depression, may be what has been mistakenly categorized as “amotivational syndrome.”

APA, Harvard, Vancouver, ISO, and other styles

38

Hernández-Serrano, Olga, Maria Eugènia Gras, Mariano Gacto, Alicia Brugarola, and Sílvia Font-Mayolas. "Family Climate and Intention to Use Cannabis as Predictors of Cannabis Use and Cannabis-Related Problems among Young University Students." International Journal of Environmental Research and Public Health 18, no. 17 (September 3, 2021): 9308. http://dx.doi.org/10.3390/ijerph18179308.

Full text

Abstract:

Determining the predictive variables associated with cannabis use and cannabis-related problems can ease the identification of young cannabis consumers who can benefit from prevention interventions. This study aimed: (1) to describe, among university students, the cannabis use and cannabis-use problems, intention to use cannabis and family climate based on the gender and the people the student lives with; (2) to explore whether the family climate and intention to use cannabis are predictors of cannabis use and cannabis-related problems. The sample was composed of 339 Spanish undergraduates (51.9% females) in a 17-to-25 age range (19.67 ± 1.53). The variables were assessed through a battery based on the ESPAD survey, cannabis abuse screening test, cannabis use intention questionnaire and family climate scale. More men than women had used cannabis in the precedent year and showed greater intention to use cannabis, whereas more women than men showed greater self-efficacy in not using cannabis. The family climate did not predict cannabis use and cannabis-related problems. However, subjective norms and self-efficacy were key predictors of cannabis use and cannabis-use problems, respectively. Different factors seemed to predict the use cannabis in the past year versus cannabis-related problems, and these differences may help inform the development and delivery of preventative efforts.

APA, Harvard, Vancouver, ISO, and other styles

39

Tyskiewicz, Alexander, Patrice Arkfeld, Emma Smith, Jonathan Eilerman, and Bradley Conner. "Does Accessibility of Cannabis Mediate the Relation Between Method of Acquisition and Cannabis Use Frequency among Adolescents?" Cannabis 5, no. 3 (November 21, 2022): 61–71. http://dx.doi.org/10.26828/cannabis/2022.03.006.

Full text

Abstract:

Cannabis use frequency among adolescents is associated with negative outcomes. Two variables associated with cannabis use frequency are method of acquisition and accessibility of cannabis. Prior research on the relation between methods of acquisition and cannabis use frequency is sparse. Differences in cannabis use in states in which the sale of recreational cannabis is legal (recreational states) compared to states in which it is not warrants research on how adolescents acquire cannabis in recreational states, and how easy it is for them to do so. The primary way in which adolescents acquire cannabis and the ease by which they can acquire cannabis may be associated with cannabis use frequency via specific interactions. We hypothesized that primarily acquiring cannabis from a store would be positively associated with cannabis use frequency when compared to other primary methods of acquisition, and that accessibility would meditate relations between primary method of acquisition and cannabis use frequency. This study used data from high school students who completed the 2019 Healthy Kids Colorado Survey (HKCS) who reported using cannabis in the past 30 days. Results indicated that primary method of acquisition was significantly differentially associated with 30-day cannabis use frequency, with participants who reported buying cannabis at a store reporting significantly higher 30-day cannabis use frequency than any other method of acquisition. Ease of accessibility was not significantly associated with 30-day cannabis use frequency and did not significantly mediate the relation between primary method of acquisition and 30-day cannabis use frequency. Results of the current study indicate that the ways in which adolescents acquire cannabis are associated with how often they use it. Further, the positive relation between primarily acquiring cannabis at stores and frequency of use provide evidence that access to stores may be a risk factor for cannabis use frequency among adolescents.

APA, Harvard, Vancouver, ISO, and other styles

40

Cohen, Nicole L., Adrienne J. Heinz, Mark Ilgen, and Marcel O. Bonn-Miller. "Pain, Cannabis Species, and Cannabis Use Disorders." Journal of Studies on Alcohol and Drugs 77, no. 3 (May 2016): 515–20. http://dx.doi.org/10.15288/jsad.2016.77.515.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Palali, Ali, and Jan C. van Ours. "Cannabis use and support for cannabis legalization." Empirical Economics 53, no. 4 (September 24, 2016): 1747–70. http://dx.doi.org/10.1007/s00181-016-1172-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Williams, Jenny, and Anne Line Bretteville-Jensen. "Does liberalizing cannabis laws increase cannabis use?" Journal of Health Economics 36 (July 2014): 20–32. http://dx.doi.org/10.1016/j.jhealeco.2014.03.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Gorman, Dennis M., and J. Charles Huber. "Do medical cannabis laws encourage cannabis use?" International Journal of Drug Policy 18, no. 3 (May 2007): 160–67. http://dx.doi.org/10.1016/j.drugpo.2006.10.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

van Ours, Jan C., and Jenny Williams. "Cannabis prices and dynamics of cannabis use." Journal of Health Economics 26, no. 3 (May 2007): 578–96. http://dx.doi.org/10.1016/j.jhealeco.2006.10.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Grotenhermen, Franjo. "The Toxicology of Cannabis and Cannabis Prohibition." Chemistry & Biodiversity 4, no. 8 (August 21, 2007): 1744–69. http://dx.doi.org/10.1002/cbdv.200790151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Knopf, Alison. "Psychosis: Cannabis‐induced, cannabis‐concurrent, or primary?" Brown University Child & Adolescent Psychopharmacology Update 22, no. 9 (August 19, 2020): 1–3. http://dx.doi.org/10.1002/cpu.30517.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Fortes, Paulo Jordão de Oliveira Cerqueira, Nelson Leal Alencar, Livio Cesar Cunha Nunes, Erik Amazonas De Almeida, Mirian Lima Dos Santos, Thomas Deeter, and Salomon Tinman. "CANNABIS THIN LAYER CHROMATOGRAPHY (TLC) CHEMO TYPING: HOW ACCURATE IS TLC COMPARED TO HIGH PRESSURE LIQUID CHROMATOGRAPHY?" Revista Contemporânea 3, no. 10 (October 29, 2023): 19702–24. http://dx.doi.org/10.56083/rcv3n10-164.

Full text

Abstract:

Problem: Brazilian Cannabis Associations (BCA) search for methods of reducing their costs and increasing their quality control of Cannabis spp. Oil and extracts. The significant difficulties presented by ABRACAM (Associação Brasileira Cannabis Medicinal) to UFPI professors were to standardize cannabinoids profiles of its plants and guarantee the same levels of cannabinoids on its artisanal extracts. ABRACAM has difficulty standardizing plant cannabinoids profiles due to Cannabis spp. Phenotypic plasticity, or the ability of Cannabis spp. to change attributes like the size of leaves, levels of secondary metabolites, stems structures, flowering period, among others. The second problem is that artisanal extract combines different production batches of non-tested extractions. It is necessary to quantify and qualify each cannabinoid and how much is on artisanal Cannabis production. Aiming to solve the ABRACAM production problem, UFPI and CANNAPI suggested manual testing practices to test cannabis and its derivates. This article results from validation tests performed at ABRACAM to determine how precise manual methods are to quantify cannabinoids. Methods: This research compared the cannabinoids results of an off-the-shelf Thin Layer Chromatography (TLC) cannabinoids profile test kit with the results of a High-Pressure Liquid Chromatography (HPLC). UFPI perfect the method from the vendor manual after running sixty quantifications from one sample. Results: The TLC error compared to HPLC was between approximately 0,5% and 1%. ABRACAM differentiated the Chemotype Profile of its High THC varieties and High CBD varieties. For High CBD variety, the outdoor cultivation proportionated greater cannabinoids levels. Conclusions: The comparison pointed that TLC may be used as testing equipment for this Brazilian Association due to its artisanal production license. This article concludes that precision is the key to medication production, and the TLC error may be accepted for artisanal production but not as a standard for precision. For scientific purposes, TLC is a strong hypothesis builder, and for agriculture, purposes may be a vital tool point the right time to harvest.

APA, Harvard, Vancouver, ISO, and other styles

48

Vedelago, Lana, Jane Metrik, and Michael Amlung. "Differentiating Medicinal and Recreational Cannabis Users via Cannabis Use Motives." Cannabis 3, no. 1 (January 31, 2020): 52–63. http://dx.doi.org/10.26828/cannabis.2020.01.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

King, Shelby, Sarah Elder, and Jenni Teeters. "Negative Cannabis Expectancies Are Associated with Drinking After Cannabis Use." Cannabis 3, no. 2 (2020): 173–79. http://dx.doi.org/10.26828/cannabis.2020.02.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Stevens, Elise, Glenn Leshner, Amy Cohn, Seunghyun Kim, and Theodore Wagener. "How Cannabis Use Status Affects Responses to Anti- Cannabis Messages." Cannabis 4, no. 2 (October 1, 2021): 1–16. http://dx.doi.org/10.26828/cannabis/2021.02.001.

Full text

Abstract:

Background: The current study examined how cannabis use status impacts cognitive and emotional reactions to public health campaigns about cannabis, and the degree to which these reactions influence message likeability and attitudes about cannabis-related harms. Methods: In a between-subjects design, 252 subjects recruited via Amazon Mechanical Turk viewed six real-world cannabis education messages: three message themes (cognitive ability, driving, and health harms) from each of two real-world public campaigns. Subjects answered questions measuring their cognitive and emotional reactions to each message as well as message likeability and harm perceptions of cannabis. Analyses examined the mediating effects of message responsiveness on the association between baseline cannabis use (user vs non-user) with indices of liking and harm. Results: For all three message themes, informativeness ratings mediated the effect of cannabis user status on the outcomes of perceived harmfulness and message likeability. Specifically, cannabis users perceived cannabis as less harmful and reported all messages as less likeable compared to non-users, partly because they perceived the messages to be less informative than non-users. Surprisingly, users found some of the messages to be more pleasant, which was associated with increased perceptions of harm and message liking compared to non-users. Conclusions: Cannabis education campaigns that take into account differences in emotional and cognitive reactions by use experience, rather than use a “one size fits all” approach, could possibly maximally impact likeability and harm perceptions of these messages.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!